Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:

Summary

Connective tissue diseases (CTD) or systemic autoimmune diseases (SADs) as they are known today are a group of chronic inflammatory conditions with autoimmune aetiology with few treatment options and difficult diagnosis.Brest team contribute to perform a new classification of the following systemic autoimmune diseases in a European Union's Seventh Framework Programme. The aim of this research is to reclassify the individuals affected by SADs into molecular clusters instead of clinical entities through the determination of molecular profiles using several "Omics" techniques.

Conditions

• Systemic Autoimmune Diseases

Sponsors & Collaborators

• UCB Biopharma S.P.R.L.

  collaborator INDUSTRY

• Atrys Health

  collaborator INDUSTRY

• National Research Council, Spain

  collaborator OTHER_GOV

• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

  collaborator OTHER

• Servicio Cántabro de Salud

  collaborator OTHER

• August Pi Sunyer Biomedical Research Institute

  collaborator OTHER

• Karolinska Institutet

  collaborator OTHER

• KU Leuven

  collaborator OTHER

• Klinikum der Universität Köln

  collaborator OTHER

• Hannover Medical School

  collaborator OTHER

• Medical University of Vienna

  collaborator OTHER

• Quartz Bio S.A.

  collaborator OTHER

• Andaluz Health Service

  collaborator OTHER_GOV

• The Cyprus Foundation for Muscular Dystrophy Research

  collaborator OTHER

• Universidad de Granada

  collaborator OTHER

• University of Milan

  collaborator OTHER

• Université Catholique de Louvain

  collaborator OTHER

• University Hospital, Brest

  collaborator OTHER

• University of Geneva, Switzerland

  collaborator OTHER

• Szeged University

  collaborator OTHER

• Bayer

  collaborator INDUSTRY

• Institut de Recherches Internationales Servier

  collaborator OTHER

• Sanofi

  collaborator INDUSTRY

• Eli Lilly and Company

  collaborator INDUSTRY

• Charite University, Berlin, Germany

  collaborator OTHER

• Centro Hospitalar do Porto

  collaborator OTHER

• Institut d'Investigació Biomèdica de Bellvitge

  collaborator OTHER

• Innovative Medicines Initiative

  collaborator OTHER

• Fundación Pública Andaluza Progreso y Salud

  lead OTHER

Principal Investigators

• Marta Alarcon · Fundación Pública Andaluza Progreso y Salud (PHFSpain)

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-12-31

Primary Completion

2017-10-31

Completion

2017-10-31

Countries

• Austria
• Belgium
• France
• Germany
• Hungary
• Italy
• Portugal
• Spain
• Switzerland

Study Locations